ABSTRACT Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis. We report the case of a 50-year-old woman who was incidentally detected to have essential thrombocytosis after suffering an episode of cerebrovascular accident with faciobrachial monoparesis. She was subsequently initiated on hydroxyurea. Within seven weeks of therapy, the patient noticed irregular hyperpigmented patches over her feet, hands and perioral region, with bluish-grey longitudinal bands on all 20 nails. Hydroxyurea-induced hyperpigmentation and melanonychia are not commonly reported. To the best of our knowledge, this is only the third published report of hydroxyurea-induced hyperpigmentation and melanonychia involving all 20 nails. Physicians need to be aware of such mucocutaneous side effects to avoid misdiagnosis and unwarranted fear in patients. The decision to discontinue the intake of the drug depends heavily on the future risk of thrombotic events.
I NTRO D U C TIO N
Hydroxyurea is an antineoplastic agent that inhibits deoxyribonucleic acid synthesis. It is commonly used for the treatment of myeloproliferative diseases such as chronic myeloid leukaemia and essential thrombocytosis.
(1) While cases of hydroxyurea-induced hyperpigmentation have been reported, reports of hydroxyurea-induced melanonychia are uncommon, with only two such cases involving all 20 nails. (2) Herein, we present one such rare scenario, where a patient developed hydroxyurea-induced hyperpigmentation and melanonychia within seven weeks after the initiation of therapy.
CA S E R EPO RT
A 50-year-old Indian woman with essential thrombocytosis complained of progressive darkening of the nails of both her hands and feet. Four months prior to this, she had suffered from right faciobrachial monoparesis. Magnetic resonance imaging of the patient's brain at that time had shown a right basal ganglia infarct.
The patient recovered completely, with no residual neurological deficits. Laboratory findings were significant for elevated platelet (ferritin 67.14 ng/mL; normal range 27-300 ng/mL) and hyperthyroidism (thyroid-stimulating hormone 4.59 UIU/mL; normal range 0.3-5 UIU/mL) were ruled out.
A diagnosis of hydroxyurea-induced hyperpigmentation was made. The acute onset of the hyperpigmentation following therapy lent support to the diagnosis. We temporarily reduced the patient's dosage of hydroxyurea to 500 mg/day and awaited her next follow-up. The complete discontinuation of the drug was avoided as we feared that it might precipitate another thrombotic event.
D I SCU S S IO N
Melanonychia due to hydroxyurea is very rarely reported when compared to skin hyperpigmentation. (3) It is more commonly seen among women. (1) While the mechanism of melanonychia is not thoroughly understood, it is hypothesised to be due to photosensitisation and direct toxicity involving the nail matrix.
A genetic predisposition is also thought to be contributory. and Tan (4) reported the occurrence of melanonychia and skin hyperpigmentation in a patient as early as seven weeks after the initiation of hydroxyurea treatment, similar to that observed in our patient. Melanonychia has also been reported as late as five years after hydroxyurea therapy. (5) In our patient, the fingernails were more involved than the toenails. This disparity has been attributed to the difference in the rate of nail growth of the hands and feet, with the toenails growing slower and therefore showing nail discolouration later. (6) In our patient, the skin hyperpigmentation was not restricted to pressure points. It occurred over the palms, and the dorsa of the hands and feet. There was perioral hyperpigmentation as well. Such presentation has been described by Gropper et al; (7) the authors reported similar findings when treating polycythaemia vera using hydroxyurea.
Interestingly, these authors also noted a gradual reduction in pigmentation despite the continuation of hydroxyurea at maximum dosage. When treating patients with melanonychia and hyperpigmentation, clinicians should take care to rule out closely mimicking conditions such as subungual melanoma, naevus, or pigmented squamous cell carcinoma.
In summary, there is a need for clinicians to be aware of the mucocutaneous side effects of hydroxyurea therapy. A correct diagnosis is essential to prevent undue fears in the patient. If necessary, therapy can be continued, even at maximum dosage, as mentioned. The decision to stop therapy needs to be carefully deliberated. It depends on the clinical setting and the physician's discretion after weighing the risk-benefit ratio.
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